Morales-Molina José Antonio, Martínez-de la Plata Juan Enrique, Urquízar-Rodríguez Olivia, Molina-Arrebola María Angustias
Pharmacy Department and.
Hematol Rep. 2011 Aug 31;3(2):e16. doi: 10.4081/hr.2011.e16. Epub 2011 Oct 10.
Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interaction between bosentan and oral anticoagulants in HIV patients has reported. So we present a case of this interaction between these drugs and we reviewed MEDLINE to identify all the papers published so far. In our case, several weeks after increasing dose of bosentan acenocoumarol dose had to be progressively increased to 70 mg/week (+33%) without obtaining an adequate INR level (2.0-3.0). Forty-nine days later, we achieved a therapeutic INR with 90 mg/week of warfarin. The use of bosentan and oral anticoagulants together in these patients require a closer monitoring during first weeks of treatment, after increasing the bosentan dose and even during longer periods of time.
肺动脉高压是一种在HIV感染中不常见但却严重危及生命的严重并发症。它可用波生坦和口服抗凝剂治疗。波生坦可诱导醋硝香豆素的代谢并增加国际标准化比值(INR)值。迄今为止,尚未有关于HIV患者中波生坦与口服抗凝剂之间相互作用的研究报道。因此,我们呈现了这样一个药物间相互作用的病例,并查阅了医学文献数据库(MEDLINE)以识别迄今发表的所有论文。在我们的病例中,增加波生坦剂量数周后,醋硝香豆素的剂量不得不逐渐增加至70毫克/周(增加了33%),但仍未获得足够的INR水平(2.0 - 3.0)。49天后,我们使用90毫克/周的华法林达到了治疗性INR。在这些患者中联合使用波生坦和口服抗凝剂时,在治疗的最初几周、增加波生坦剂量后甚至更长时间段内都需要更密切的监测。